Posted: December 17, 2020 at 7:55 am
QuantuMDx embarks on £11 million scale-up to mass manufacture its diagnostic Q-POCTM device and disposable test cassette
Excerpt from:
QuantuMDx embarks on £11 million scale-up to mass manufacture its diagnostic Q-POCTM device and disposable test cassette
Posted: December 17, 2020 at 7:55 am
Company Anticipates NDA Resubmission in February 2021 Company Anticipates NDA Resubmission in February 2021
Read the rest here:
Avenue Therapeutics Provides Regulatory Update for IV Tramadol
Posted: December 17, 2020 at 7:55 am
Company plans to initiate a Phase 1/2 trial of SIG-005 in patients with mucopolysaccharidosis type I (MPS-1) in the second half of 2021 Company plans to initiate a Phase 1/2 trial of SIG-005 in patients with mucopolysaccharidosis type I (MPS-1) in the second half of 2021
Originally posted here:
Sigilon Therapeutics Receives Orphan Drug Designation for SIG-005 for the Treatment of Mucopolysaccharidosis Type I
Posted: December 17, 2020 at 7:55 am
SAN DIEGO, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced positive top-line results from the Phase 1/2 clinical trial of OTO-413 in subjects with speech-in-noise hearing difficulty. The randomized, double-blind, placebo-controlled trial demonstrated that a single intratympanic injection of OTO-413, a sustained exposure formulation of brain-derived neurotrophic factor (BDNF), was well-tolerated across all dose cohorts. Furthermore, there was demonstration of therapeutic activity of OTO-413 versus placebo across multiple clinically-validated speech-in-noise hearing tests at consecutive time points (Days 57 and 85). Based on these results, the company plans to continue development of OTO-413 for the treatment of hearing loss.
Posted: December 17, 2020 at 7:55 am
Company obtains exclusive rights to develop and commercialize antibody therapeutics targeting insulin-like growth factor-1 receptor (IGF-1R) using Xencor’s Xtend™ half-life extension technology
Posted: December 17, 2020 at 7:55 am
Company to present corporate update and plans for 2021
Read more:
BioXcel Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
Posted: December 17, 2020 at 7:55 am
WATERTOWN, Mass., Dec. 17, 2020 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule drugs that selectively destroys disease-causing proteins through degradation, today announced that the Company will be added to the Russell 2000® and Russell 3000® Indexes as part of the Russell quarterly update, effective December 21, 2020.
View original post here:
C4 Therapeutics to be Added to the Russell 2000® and Russell 3000® Indexes
Posted: December 17, 2020 at 7:55 am
BELTSVILLE, Md., Dec. 17, 2020 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today provided an update on the clinical trial program for NC318, its first-in-class immunomedicine against Siglec15 (S15), a novel immunomodulatory target.
Excerpt from:
NextCure Provides Updates on NC318 Clinical Program
Posted: December 17, 2020 at 7:55 am
SAN DIEGO, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products in women’s health, today announced that it is expanding the availability of COVID-19 RT-PCR testing across the United States to support the rising demand for testing.
Original post:
Progenity Expands Availability of COVID-19 PCR Testing Services Across United States
Posted: December 17, 2020 at 7:55 am
Read the rest here:
Kolab Project Launches 232 Series Limited Edition Live Terpene 510 Vape Cartridges
